<DOC>
	<DOCNO>NCT02814097</DOCNO>
	<brief_summary>This multi-center , randomize , double-blind , placebo-controlled study subject stable heart failure preserve ejection fraction ( HFpEF ) evaluate effect 4 week treatment subcutaneous MTP-131 ( elampretide ) leave ventricular function .</brief_summary>
	<brief_title>A Study Evaluate Effects 4 Weeks Treatment With Subcutaneous Elamipretide Left Ventricular Function Subjects With Stable Heart Failure With Preserved Ejection Fraction</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Age ≥45 &lt; 80 year . Symptomatic heart failure ( i.e . NYHA II III ) due HFpEF least 6 month prior study start Evidence HFpEF : LVEF ≥45 % E/e´ &gt; 10 NTproBNP &gt; 220 pg/ml ( sinus rhythm ) / &gt; 600 pg/mL ( atrial fibrillation ) An exerciseinduced increase E/e ' least 1.5 unit stress echocardiography assessment . Heart failure consider stable , judgment investigator , hospitalization HFpEF change dose regimen pharmacologic treatment HF occur within 1 month prior Screening Visit . Treatment appropriate pharmacologic therapy manage underlying risk factor accord current guideline . Women childbearing potential must agree use 1 follow method birth control date sign ICF two month last dose study medication : ) Abstinence , b ) surgically sterilize male partner , c ) barrier method And hormonal contraception Women childbearing potential must negative serum pregnancy test baseline Willing able provide sign informed consent form ( ICF ) prior participation studyrelated procedure Probable alternative diagnosis opinion investigator could account patient 's symptom e.g . severe pulmonary dysfunction severe asthma LVEF &lt; 45 % ( moment enrollment medical history ) Coronary peripheral revascularization procedure , valvular procedure , OR major surgical procedure within 3 month prior Screening Visit . Acute coronary syndrome ( ACS ) , stroke transient ischemic attack ( TIA ) within 3 month prior Screening Visit . Uncontrolled hypertension define systolic blood pressure ( BP ) &gt; 160 mm Hg diastolic BP &gt; 100 mm Hg least 2 consecutive reading require change antihypertensive treatment study period . Active cancer undergo chemotherapy within previous 6 month Total bilirubin &gt; 2x upper limit normal ( ULN ) absence Gilbert 's Syndrome ( M. Meulengracht ) liver enzyme ( alanine aminotransferase [ ALT ] and/or aspartate aminotransferase [ AST ] and/or alkaline phosphatase ) elevation &gt; 3xULN Estimated glomerular filtration rate &lt; 30 mL/min , MDRD Known active drug alcohol abuse within 1 year Screening Visit . Use investigational drug time enrolment , within 30 day 5 halflives enrolment Treatment spironolactone eplerenone less 3 month study start Treatment dabigatran Treatment valsartan/sacubitril Female subject pregnant , plan become pregnant , lactate .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Heart Failure</keyword>
	<keyword>HFpEF</keyword>
	<keyword>elamipretide</keyword>
	<keyword>MTP-131</keyword>
	<keyword>Bendavia™</keyword>
</DOC>